All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Synthekine Inc., a California startup developing new medicines for cancer and autoimmune disorders, has closed an $82 million series A financing. The funds will help the company move its two lead programs into the clinic, expand its discovery pipeline and hone its cytokine engineering platforms.